Paris saponin II inhibits human ovarian cancer cell‑induced angiogenesis by modulating NF-κB signaling

Yang,Mei; Zou,Juan; Zhu,Hongmei; Liu,Shanling; Wang,He; Bai,Peng; Xiao,Xue

doi:10.3892/or.2015.3836

Paris saponin II inhibits human ovarian cancer cell‑induced angiogenesis by modulating NF-κB signaling

Authors:
- Mei Yang
- Juan Zou
- Hongmei Zhu
- Shanling Liu
- He Wang
- Peng Bai
- Xue Xiao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: March 5, 2015 https://doi.org/10.3892/or.2015.3836
Pages: 2190-2198

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical applications of Rhizoma paridis in traditional Chinese medicine are well known. However, the therapeutic potential of Rhizoma paridis and its active component such as Paris saponin I (polyphyllin D) and Paris saponin II (PSII) (formosanin C) in cancer treatments have not yet been fully explored. Recent studies have demonstrated that PSII and chemoagents exhibit comparable inhibitory affects against human ovarian cancer cell growth. Since NF-κB, a ubiquitous transcription factor that plays an important role in cancer biology, is often associated with gynecological cancers, in the present study, we evaluated the possibility that PSII modulates NF-κB activity and VEGF-mediated angiogenesis and elucidated the molecular mechanisms underlying such effects. We assessed the effects of PSII on NF-κB activity in SKOV3 tumor cells and on tumor cell induced-angiogenesis using standardized angiogenesis in vitro, ex vivo and in vivo assays, western blot analysis and kinase assay. We also assessed the effect of the super-engineered repressor of IĸBα and its effect, in combination with PSII treatment on tumor growth and angiogenesis in xenograft athymic mouse models of ovarian cancer (SKOV3 and SKOV3/mutant IĸBα cells) using color Doppler ultrasound and traditional immunohistochemistry. We showed that PSII suppressed NF-κB activation as a result of the reduction in IKKβ kinase activity on its substrate IκBα and the expression of IKKβ. Compromising NF-κB activation reduced the expression of NF-κB-downstream targets such as VEGF, Bcl-2 and Bcl-xL. Such inhibitory effects at molecular levels appear to compromise tumor growth and angiogenesis. Most importantly, the combination of PSII treatment and constitutive repression of IĸBα activity exhibited marked inhibitory effects against human ovarian cancer cell growth in a xenograft mouse model of ovarian cancer. For the first time, we provide evidence showing that PSII potently inhibits angiogenesis and the growth of human ovarian cancer by suppressing NF-κB signaling.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
3	Eckstein N: Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res. 30:912011. View Article : Google Scholar : PubMed/NCBI
4	Carmeliet P: Angiogenesis in life, disease and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
6	Xu W, Liu LZ, Loizidou M, Ahmed M and Charles IG: The role of nitric oxide in cancer. Cell Res. 12:311–320. 2002. View Article : Google Scholar
7	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
8	Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60:5334–5339. 2000.PubMed/NCBI
9	Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
10	Yu HG, Yu LL, Yang Y, et al: Increased expression of RelA/nuclear factor-κB protein correlates with colorectal tumorigenesis. Oncology. 65:37–45. 2003. View Article : Google Scholar
11	Biswas DK, Shi Q, Baily S, et al: nf-κb activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA. 101:10137–10142. 2004. View Article : Google Scholar
12	Gilmore TD, Koedood M, Piffat KA and White DW: Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene. 13:1367–1378. 1996.PubMed/NCBI
13	Yang G, Xiao X, Rosen DG, et al: The biphasic role of nf-κb in progression and chemoresistance of ovarian cancer. Clin Cancer Res. 17:2181–2194. 2011. View Article : Google Scholar : PubMed/NCBI
14	Scherer DC, Brockman JA, Chen Z, Maniatis T and Ballard DW: Signal-induced degradation of IκBα requires site-specific ubiquitination. Proc Natl Acad Sci USA. 92:11259–11263. 1995. View Article : Google Scholar
15	Brown K, Gerstberger S, Carlson L, Franzoso G and Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 267:1485–1488. 1995. View Article : Google Scholar : PubMed/NCBI
16	Brockman JA, Scherer DC, McKinsey TA, et al: Coupling of a signal response domain in iκbα to multiple pathways for nf-κb activation. Mol Cell Biol. 15:2809–2818. 1995.PubMed/NCBI
17	Huang S, Pettaway CAUH, Bucana CD and Fidler IJ: Blockade of nf-κb activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 20:4188–4197. 2001. View Article : Google Scholar : PubMed/NCBI
18	Fujioka S, Sclabas GM, Schmidt C, et al: Function of nuclear factor κb in pancreatic cancer metastasis. Clin Cancer Res. 9:346–354. 2003.PubMed/NCBI
19	Ho JW, Leung YK and Chan CP: Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents. 2:209–214. 2002. View Article : Google Scholar
20	Man S, Gao W, Zhang Y, et al: Antitumor and antimetastatic activities of Rhizoma Paridis saponins. Steroids. 74:1051–1056. 2009. View Article : Google Scholar : PubMed/NCBI
21	Cosgrove D: Angiogenesis imaging - ultrasound. Br J Radiol. 76(Spec No 1): S43–S49. 2003. View Article : Google Scholar
22	Howard-Claudio C: MRI methods for the detection of angiogenesis. Supplement to Appl Radiol. 34:2005.
23	Man S, Gao W, Zhang Y, et al: Characterization of steroidal saponins in saponin extract from Paris polyphylla by liquid chromatography tandem multi-stage mass spectrometry. Anal Bioanal Chem. 395:495–505. 2009. View Article : Google Scholar : PubMed/NCBI
24	Xiao X, Bai P, Bui Nguyen TM, et al: The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther. 8:1179–1188. 2009. View Article : Google Scholar : PubMed/NCBI
25	Xiao X, Zou J, Bui-Nguyen TM, et al: Paris saponin II of Rhizoma Paridis - a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends. 6:201–211. 2012. View Article : Google Scholar : PubMed/NCBI
26	Schmitt J and Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev. 38:272–283. 2012. View Article : Google Scholar
27	Nicosia RF and Ottinetti A: Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. 63:115–122. 1990.PubMed/NCBI
28	Xiao X, Yang M, Xiao J, et al: Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration. Cancer Chemother Pharmacol. 73:807–818. 2014. View Article : Google Scholar : PubMed/NCBI
29	Agbottah E, Yeh WI, Berro R, et al: Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways. AIDS Res Ther. 5:122008. View Article : Google Scholar : PubMed/NCBI
30	Patan S: Vasculogenesis and angiogenesis. Cancer Treat Res. 117:3–32. 2004. View Article : Google Scholar : PubMed/NCBI
31	Fujioka S, Sclabas GM, Schmidt C, et al: Inhibition of constitutive nf-κb activity by iκbα M suppresses tumorigenesis. Oncogene. 22:1365–1370. 2003. View Article : Google Scholar : PubMed/NCBI
32	Wen F, Yin H, Chen C, et al: Chemical characteristics of saponins from Paris fargesii var. brevipetala and cytotoxic activity of its main ingredient, paris saponin H. Fitoterapia. 83:627–635. 2012. View Article : Google Scholar : PubMed/NCBI
33	Nor JE, Christensen J, Mooney DJ and Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 154:375–384. 1999. View Article : Google Scholar : PubMed/NCBI
34	Nör JE, Christensen J, Liu J, et al: Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 61:2183–2188. 2001.PubMed/NCBI
35	Karl E, Warner K, Zeitlin B, et al: Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines. Cancer Res. 65:5063–5069. 2005. View Article : Google Scholar : PubMed/NCBI
36	Lacouture ME, Lenihan DJ and Quaggin SE: Antiangiogenic Therapy: Tolerability and Management of Side Effects. 2009, http://www.angioorg/pdf/Angio_Poster_Final_6-30.pdfurisimplewww.angioorg/pdf/Angio_Poster_Final_6-30.pdf.